BioNTech announced plans to acquire CureVac for $1.25 billion in an all-stock deal, consolidating two mRNA-focused biotechs. This acquisition enhances BioNTech's pipeline in cancer immunotherapy and infectious disease vaccines by integrating CureVac's proprietary mRNA technologies and assets. The deal signifies a strategic move to expand capabilities and address unmet needs in oncologic and vaccine therapeutics within the rapidly evolving RNA therapeutics market.